# A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

> **NCT03357380** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 67 (actual)

## Conditions studied

- Hepatobiliary Disorders
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03357380
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-28
- **Primary completion:** 2020-03-20
- **Final completion:** 2020-03-20
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357380, "A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03357380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*